Novo Nordisk closes deal on technology platform
![Photo: Stine Tidsvilde](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13098872.ece/ALTERNATES/schema-16_9/doc7gg99meyeud17v04dlvr.jpg)
The collaborative agreement between Novo Nordisk and the global company SomaLogic means that the Danish pharmaceutical company can use the technology platform SomaScan for the development of treatments, for example (NASH), cardiovascular diseases and diabetes, according to a SomaLogic press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk sticks to cautious obesity sales goal
For subscribers